RPL21P97: A Potential Drug Target and Biomarker for Various Diseases

Target Name: RPL21P97

NCBI ID: G387753

RPL21P97

Other Name(s): RPL21_40_1120 | Ribosomal protein L21 pseudogene 97 | ribosomal protein L21 pseudogene 97

RPL21P97: A Potential Drug Target and Biomarker for Various Diseases

RPL21P97 (RPL21_40_1120) is a protein that is expressed in various tissues of the human body, including the brain, heart, and liver. It is a member of the RPL21 family, which is known for its role in regulating microRNA (miRNA) expression. RPL21P97 is highly conserved across various species, and its sequence has been used to identify potential drug targets or biomarkers. In this article, we will discuss the potential drug target profile of RPL21P97 and its potential as a biomarker for various diseases.

Potential Drug Target Profile

RPL21P97 is a protein that has been shown to play a role in the regulation of miRNA expression. MiRNA is a small non-coding RNA molecule that plays a crucial role in post-transcriptional gene regulation by silencing coding RNA. It is expressed in various tissues of the body and has been implicated in various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.

Studies have shown that RPL21P97 is involved in the regulation of miRNA expression by binding to the target miRNA and affecting its stability. RPL21P97 has been shown to interact with miR-202, a known regulator of miRNA expression. This interaction between RPL21P97 and miR-202 has led to the prediction that RPL21P97 may be a potential drug target for the treatment of various diseases associated with miRNA dysregulation.

Potential Biomarkers

RPL21P97 has also been shown to be involved in the regulation of cellular processes that are relevant to various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. This involvement in these processes makes RPL21P97 potential as a biomarker for these diseases.

Studies have shown that RPL21P97 is involved in the regulation of cell proliferation, apoptosis, and angiogenesis. RPL21P97 has been shown to play a role in the regulation of theNotch signaling pathway, a pathway that is involved in the regulation of cellular processes that are critical for cancer progression.

In addition, RPL21P97 has also been shown to be involved in the regulation of the TGF-β pathway, a pathway that is involved in the regulation of cellular processes that are critical for neurodegenerative diseases. The TGF-β pathway is known to play a role in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

Conclusion

In conclusion, RPL21P97 is a protein that has been shown to play a role in the regulation of miRNA expression and cellular processes that are relevant to various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. Its potential as a drug target or biomarker makes it an attractive target for future research. Further studies are needed to determine the full role of RPL21P97 in these diseases and its potential as a drug or biomarker.

Protein Name: Ribosomal Protein L21 Pseudogene 97

The "RPL21P97 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL21P97 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets